Gene: GRIK4

2900
EAA1|GRIK|GluK4|KA1
glutamate ionotropic receptor kainate type subunit 4
protein-coding
11q23.3
Ensembl:ENSG00000149403 MIM:600282 Vega:OTTHUMG00000048255 UniprotKB:Q16099
NG_042194.1
PubMed|SNP Mapped
2   ANCO-SNPs
ND|AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.808e-1 (AD)  6.742e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs7103228chr11:120710058 (GRCh38.p7)G>A / G>Tnicotine dependenceSNV(Single Nucleotide Variation)
rs11217974chr11:120691780 (GRCh38.p7)A>Gnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ASIC10.744
NDST10.736
NAV10.713
PTPRS0.712
IPO130.71
XPO60.71
MDGA10.709
NLGN30.706
GRID10.705
COLGALT20.704

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.504
OR4F29-0.444
C19orf33-0.352
HBD-0.319
CLEC2B-0.307
OR6C74-0.28
VNN2-0.276
FCGR3B-0.275
S100A12-0.272
BCL2A1-0.267

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00142Glutamic AcidSmall Molecule56-86-0Approved|NutraceuticalTarget
ID Drug Name Action PubMed
C006632arsenic trioxidearsenic trioxide results in increased expression of GRIK4 mRNA20458559
D001564Benzo(a)pyreneAHR protein affects the reaction [Benzo(a)pyrene affects the expression of GRIK4 mRNA]22228805
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of GRIK4 mRNA22228805
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIK4 mRNA25607892
C006780bisphenol Abisphenol A results in decreased expression of GRIK4 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of GRIK4 gene28505145
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIK4 mRNA25607892
D002392Catechin[Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of GRIK4 mRNA24763279
D000068579Celecoxib[Celecoxib co-treated with Kainic Acid] results in decreased expression of GRIK4 mRNA21589914
D004390ChlorpyrifosChlorpyrifos results in decreased expression of GRIK4 mRNA17452286
D004390ChlorpyrifosChlorpyrifos results in increased expression of GRIK4 mRNA19440498
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of GRIK4 gene20938992
D003471CuprizoneCuprizone results in decreased expression of GRIK4 mRNA26577399
D003976DiazinonDiazinon affects the expression of GRIK4 mRNA19440498
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIK4 mRNA25607892
D000431EthanolEthanol results in decreased expression of GRIK4 mRNA20655511
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of GRIK4 gene20938992
C511402Grape Seed Proanthocyanidins[Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of GRIK4 mRNA24763279
D006220HaloperidolHaloperidol results in increased expression of GRIK4 mRNA15860345
D007608Kainic Acid[Celecoxib co-treated with Kainic Acid] results in decreased expression of GRIK4 mRNA21589914
D007608Kainic AcidKainic Acid results in decreased expression of GRIK4 mRNA21589914
D007657Ketone BodiesKetone Bodies results in increased expression of GRIK4 mRNA16807920
D007854LeadLead affects the expression of GRIK4 mRNA28903495
D007854LeadLead affects the methylation of GRIK4 gene24519525
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of GRIK4 gene20938992
D008748MethylcholanthreneMethylcholanthrene promotes the reaction [AHR protein binds to GRIK4 promoter]20348232
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of GRIK4 mRNA"20188158
C028007nickel monoxidenickel monoxide results in increased expression of GRIK4 mRNA19167457
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIK4 mRNA25607892
D014284TriiodothyronineTriiodothyronine results in increased expression of GRIK4 mRNA23397585
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of GRIK4 mRNA21570461
D014635Valproic AcidValproic Acid results in increased methylation of GRIK4 gene29154799
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of GRIK4 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005234extracellularly glutamate-gated ion channel activity-IEA-  
GO:0008066glutamate receptor activity-IBA21873635  
GO:0015276ligand-gated ion channel activity-TAS-  
GO:0015277kainate selective glutamate receptor activity-IBA21873635  
GO:0015277kainate selective glutamate receptor activity-TAS8263508  
GO:1904315transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0007215glutamate receptor signaling pathway-TAS8263508  
GO:0007268chemical synaptic transmission-TAS8263508  
GO:0034220ion transmembrane transport-IEA-  
GO:0035235ionotropic glutamate receptor signaling pathway-IEA-  
GO:0035249synaptic transmission, glutamatergic-IBA21873635  
GO:0050804modulation of chemical synaptic transmission-IBA21873635  
GO:0060079excitatory postsynaptic potential-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-IBA21873635  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-TAS8263508  
GO:0030054cell junction-IEA-  
GO:0032983kainate selective glutamate receptor complex-IBA21873635  
GO:0032983kainate selective glutamate receptor complex-IEA-  
GO:0042734presynaptic membrane-IBA21873635  
GO:0042734presynaptic membrane-IEA-  
GO:0045211postsynaptic membrane-IBA21873635  
GO:0045211postsynaptic membrane-IEA-  
GO:0098839postsynaptic density membrane-IBA21873635  
KEGG ID KEGG Term
hsa04080Neuroactive ligand-receptor interaction
Reactome ID Reactome Term Evidence
R-HSA-112314Neurotransmitter receptors and postsynaptic signal transmissionTAS
R-HSA-112315Transmission across Chemical SynapsesTAS
R-HSA-112316Neuronal SystemTAS
R-HSA-451306Ionotropic activity of kainate receptorsTAS
R-HSA-451308Activation of Ca-permeable Kainate ReceptorTAS
R-HSA-451326Activation of kainate receptors upon glutamate bindingTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
29032150Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases. (2018 Jan 30)Sundararajan TGene